AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Aug 11, 2021

HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session

Pushing the frontiers of research, science, and technology.


Hensin Tsao, MD, PhD, FAAD
Hensin Tsao, MD, PhD, FAAD

The latest breakthroughs and innovations in skin science and technology were front and center for the Aug. 7 session,  “Frontiers in Research, Science and Technology (FiRST)” (S011). Compared to the late-breaking abstract sessions, “the FiRST session is traditionally smaller, nimbler, and more willing to push earlier stage data, especially in the areas of technology and artificial intelligence,” said Hensin Tsao, MD, PhD, FAAD, the session’s co-moderator. Dr. Tsao is the Richard Allen Johnson, MD Endowed Chair in Dermatology, and head of the Skin Cancer Genetics Laboratory/Wellman Center for Photomedicine at Massachusetts General Hospital in Boston.       Aad Plenary Speakers[46]    

The FiRST session featured results from clinical and pediatric studies, and insights on basic science, cutaneous oncology, and procedural dermatology. Here’s a brief summary of four of the 11 presentations.

HPV vaccination and dermatologic surgery

“Mounting evidence suggests that HPV DNA can be transmitted via the surgical plume created during dermatologic surgery, such as laser procedures and electrosurgery,” said Ross L. Pearlman, MD, a PGY4 dermatology resident at the University of Mississippi Medical Center in Jackson. Dr. Pearlman presented results from a survey study of American College of Mohs Surgery members: “Adoption of Human Papillomavirus Vaccination Among Dermatologic Surgeons.” According to the survey, most dermatologic surgeons in the cohort were not vaccinated against HPV. Cases have been reported of surgeons who have developed HPV-positive cancers of the head and neck.            

“Changing expert recommendations suggest that HPV vaccination should not just be based on age and sex, but also on occupational risk,” Dr. Pearlman said. “To help surgeons make educated decisions about vaccination, it would be helpful if our own organization, the American Society for Dermatologic Surgery and the American College of Mohs Surgery, developed evidence-based recommendations for HPV vaccination.” Meanwhile, “surgeons need to decide for themselves whether vaccinating based on their occupational risk is right for them,” Dr. Pearlman said.

Bimekizumab shows promise for psoriasis

“We have another dramatic, new effective treatment for psoriasis,” said Mark Lebwohl, MD, FAAD, dean for clinical therapeutics and chairman emeritus in the department of dermatology at Icahn School of Medicine at Mount Sinai in New York City. Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. Dr. Lebwohl reported the results of a preliminary study, which followed patients with psoriasis undergoing bimekizumab therapy who achieved clear or almost clear body surface area of less than 1% and their Psoriasis Area and Severity Index (PASI) scores.            

“Patients who achieved clear or almost clear body surface area of less than 1% and PASI 100 at week 16, who were almost clear, was 87.5%,” Dr. Lebwohl said. “When you followed them for two years, the proportion of patients who were still clear or almost clear was 90%. These dramatic benefits show a durable response to bimekizumab.”

AD treatment improves quality of life

The disease burden of severe atopic dermatitis (AD) is well-recognized to extend beyond the patient to other members of the household, particularly parents and caregivers of children with AD. Carden Simcox, PhD, associate director of field medical affairs at Regeneron, shared results from a Phase 3 study of dupilumab with concomitant topical corticosteroids (TCS) in pediatric patients 6 to 11 years of age with severe AD, which included an analysis of the quality of life of their families and caregivers.

“The results showed dupilumab added to TCS in children 6 to 11 years with severe AD improved family quality of life measures for the caregiver and family across all domains assessed, with continued improvement through the 16-week treatment period,” Dr. Simcox said. Dupilumab is the first approved biologic for moderate to severe AD in children 6 to 11 years. “These results show its potential to help reduce the burden on caregivers and improve family quality of life,” Dr. Simcox said.

Potential risk of biologic agents

Research suggests the development of cutaneous T cell lymphomas following exposure to a biologic agent. “While it’s a rare complication, it’s still a complication nonetheless,” said Lauren Schaefer, a fourth-year medical student at Mayo Clinic School of Medicine in Rochester, Minnesota. Schaefer reported on a study examining the number of patients at her institution who developed cutaneous lymphoma after exposure to biologic agents. “We don’t fully understand all of the ramifications of biologic agents, but it’s important to improve clinician awareness so we’re better stewards of these drugs,” Schaefer said. 

Interesting Stories
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Julie Gerberding, MD, MPH
Summer Meeting 2021
COVID-19: A “predictable surprise”
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Alina G. Bridges, DO, FAAD
Summer Meeting 2021
New science, technology, and dedication improve dermatopathology
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Summer Meeting 2021
Lessons from COVID-19’s cutaneous manifestations
Aug 05, 2021
Charlene Lam, MD, MPH, FAAD
Summer Meeting 2021
“Uninvite” disaster by planning
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.